Core Viewpoint - Nukkleus, Inc. has announced its majority ownership of the sponsor of a newly formed SPAC, SC II Acquisition Corp, which has filed for an IPO to raise $150 million [1][2]. Group 1: Company Overview - Nukkleus, Inc. is the majority owner of SC II Acquisition Corp, a newly formed SPAC [1]. - Menachem Shalom, the CEO of Nukkleus, is expected to serve as the CEO of SC II [3]. Group 2: IPO Details - SC II intends to raise $150 million through the sale of units, with each unit priced at $10.00, consisting of one Class A ordinary share and a right to receive one-fifth of a Class A ordinary share upon a business combination [2]. - The underwriters will have an option to purchase an additional $22.5 million of units in the proposed IPO [2]. - SC II plans to list its units on the Nasdaq Global Market under the symbol "SCIIU" [2]. Group 3: Regulatory Information - A registration statement on Form S-1 has been filed with the SEC but is not yet effective, meaning securities cannot be sold or offers accepted until it becomes effective [4]. - The preliminary prospectus related to the offering will be available from D. Boral Capital LLC [3].

Core Viewpoint - GlobalTech Corporation has appointed D. Boral Capital LLC as its strategic advisor for a proposed private placement, which is seen as a significant step towards achieving its uplisting objective and enhancing its capital markets profile [1][2][3] Group 1: Company Overview - GlobalTech Corporation is a U.S.-based technology holding company focused on artificial intelligence (AI), big data, and emerging technologies [1][5] - The company aims to empower visionary companies and innovation-led enterprises through strategic partnerships and capital investment [5] Group 2: Strategic Advisor Role - D. Boral Capital will assist GlobalTech in structuring and executing the proposed private placement, utilizing its institutional network to support GlobalTech's growth [2][3] - The placement is expected to provide resources for GlobalTech's strategic priorities, including AI product development, international market expansion, and targeted acquisitions [2] Group 3: Leadership Perspective - Dan Green, CEO of GlobalTech, expressed confidence that D. Boral's support will aid in achieving the company's uplisting goals and align with its ambitions for global scaling and long-term shareholder value [3]

Core Viewpoint - Aduro Clean Technologies Inc. has successfully completed an underwritten public offering, raising approximately US$1.2 million through the issuance of additional common shares and warrants, which will be utilized for research and development, construction of a demonstration-scale plant, and general corporate purposes [1][3]. Group 1: Offering Details - The company issued 142,180 common shares and 71,090 warrants, with each whole warrant exercisable into one common share at an exercise price of US$10.13, expiring three years from issuance [1][2]. - The offering was managed by D. Boral Capital LLC, which acted as the sole book-running manager [2]. Group 2: Use of Proceeds - The net proceeds from the offering will be allocated to ongoing research and development costs, expenditures for the construction of the demonstration-scale plant, and any remaining funds for general corporate purposes and working capital [3]. Group 3: Regulatory Information - The offering was conducted under an effective shelf registration statement filed with the U.S. Securities and Exchange Commission (SEC) and a Canadian short form base shelf prospectus, both effective as of May 28, 2025 [4][5]. - The securities were offered and sold exclusively in the United States, with no sales to Canadian purchasers [4]. Group 4: Company Overview - Aduro Clean Technologies specializes in patented water-based technologies aimed at chemically recycling waste plastics, converting heavy crude and bitumen into lighter oil, and transforming renewable oils into higher-value fuels or chemicals [8]. - The company's Hydrochemolytic™ Technology utilizes water as a key agent in a low-temperature chemistry platform, providing a cost-effective solution for converting low-value feedstocks into valuable resources [8].

Core Viewpoint - FibroBiologics, Inc. has successfully closed the third $5 million tranche of a Standby Equity Purchase Agreement (SEPA) with Yorkville Advisors, allowing the company to raise up to $25 million over two years for its therapeutic development efforts [1][2]. Financing Details - The SEPA allows FibroBiologics to sell up to $25 million in common stock to Yorkville over two years, with the first three tranches totaling $15 million being advanced in equal parts of $5 million each [2]. - The third tranche of $5 million was funded after the effectiveness of a registration statement and shareholder approval, complying with Nasdaq rules [2]. Use of Proceeds - The net proceeds from this financing are intended for general corporate purposes, including funding research and development programs and supporting an upcoming Phase 1/2 clinical trial for diabetic foot ulcers expected to start in the second half of 2025 [3]. Company Overview - FibroBiologics is a clinical-stage biotechnology company based in Houston, focusing on developing therapeutics and potential cures for chronic diseases using fibroblast cells and fibroblast-derived materials [7][8]. - The company holds over 275 patents issued and pending, covering various clinical pathways such as wound healing, multiple sclerosis, and cancer [8].

Core Viewpoint - DigiAsia Corp. has appointed D. Boral Capital as the exclusive placement agent for a proposed capital raise of up to $100 million to establish and manage a Bitcoin treasury reserve, marking a significant corporate crypto treasury initiative in 2025 [1][3]. Group 1: Company Strategy - The capital raised will be allocated to DigiAsia's Bitcoin treasury reserve, which is one of the most significant initiatives launched by a NASDAQ-listed firm in 2025 [1]. - The appointment of D. Boral Capital reflects DigiAsia's commitment to partnering with experienced capital markets advisors to accelerate its treasury transformation through digital assets [2]. - DigiAsia aims to solidify its position as a pioneer in regulated corporate crypto treasury strategy, with plans to complete the initial raise and begin Bitcoin acquisitions in Q3 2025 [3]. Group 2: Financial Structure and Execution - D. Boral Capital will lead the structuring, syndication, and placement of the financing strategy, which includes equity-linked offerings, convertible instruments, and institutional crypto finance solutions [2]. - The treasury will be deployed through a secure, yield-generating structure utilizing licensed digital asset custodians and financial institutions [3]. - Investor outreach and institutional allocation programs are set to commence immediately as part of the capital raise process [4]. Group 3: Company Background - DigiAsia Corp. is a Nasdaq-listed fintech-as-a-service platform that delivers digital banking, payments, and embedded finance solutions across Southeast Asia and emerging markets [5]. - The company is expanding into AI-driven finance and crypto-enabled treasury solutions, indicating a forward-looking approach to financial technology [5]. - D. Boral Capital is a global investment bank dedicated to providing strategic advisory and tailored financial solutions to middle-market and emerging growth companies [6].

As filed with the U.S. Securities and Exchange Commission on May 16, 2025 Registration No. 333-286795 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO. 1 TO FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 WINTERGREEN ACQUISITION CORP. (Exact name of registrant as specified in its charter) Cayman Islands 6770 N/A (Primary Standard Industrial Classification Code Number) (I.R.S. Employer Identification Number) Room 8326, Block B, Hongxiang Cultural and Creat ...

As filed with the U.S. Securities and Exchange Commission on May 16, 2025 Registration No. 333-286795 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO. 1 TO FORM S-1 Room 8326, Block B, Hongxiang Cultural and Creative Industrial Park, 90 Jiukeshu West Road, Tongzhou District, Beijing, PRC (Address, including zip code, and telephone number, including area code, of registrant's principal executive offices) Puglisi & Associates 850 Library Avenue, Suite 204 Newark, DE 19711 ...

Company Overview - NanoViricides, Inc. is a clinical stage company focused on developing broad-spectrum antivirals using host-mimetic nanomedicine technology that viruses cannot escape [2][4] - The company has developed NV-387, a novel antiviral drug that has completed Phase I human clinical trials and is preparing for a Phase II trial for treating MPox in Africa [4] - Additional clinical trials for NV-387 are planned for RSV, Influenza, COVID, and other respiratory infections, with expectations for efficacy against Measles virus as well [4] - The company also developed NV-HHV-1 for herpesvirus infections and NV-HIV-1 for HIV/AIDS treatment [4] - The overall market size for NV-387, NV-HHV-1, and NV-HIV-1 is estimated to be between $20 to $30 billion [4] Event Participation - NanoViricides will participate in the D. Boral Capital Inaugural Global Conference on May 14, 2025, at The Plaza Hotel in New York City [2] - Anil R. Diwan, President & Executive Chairman, will host one-on-one meetings during the conference from 9:00 A.M. to 3:00 P.M. (ET) [3]

Core Viewpoint - Worksport Ltd. is participating in the D. Boral Capital Inaugural Global Conference on May 14, 2025, in New York City, which is expected to attract investors and feature keynote speaker Kevin O'Leary [1][2]. Company Overview - Worksport Ltd. (NASDAQ: WKSP) designs, develops, manufactures, and owns intellectual property for various products, including tonneau covers, solar integrations, portable power systems, and clean heating & cooling solutions [3]. - The company has a partnership with Hyundai for the SOLIS Solar cover and offers a hard-folding cover compatible with all major truck models, gaining traction in the electric vehicle sector [3]. - Worksport aims to leverage the growing consumer shift towards clean energy with its proprietary solar solutions, mobile energy storage systems, and Cold-Climate Heat Pump technology [3]. D. Boral Capital Overview - D. Boral Capital LLC is an investment bank based in New York, providing advisory and financing solutions to middle market and emerging growth companies [4]. - The firm has a strong track record, having aggregated over $25 billion in capital across approximately 350 transactions [5].

As filed with the U.S. Securities and Exchange Commission on April 28, 2025 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 WINTERGREEN ACQUISITION CORP. (Exact name of registrant as specified in its charter) Cayman Islands 6770 N/A (State or other jurisdiction of incorporation or organization) (Primary Standard Industrial Classification Code Number) (I.R.S. Employer Identification Number) Room 832 ...